巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Can-Fite BioPharma Ltd

    CANF
    0.914
    0.020
    2.15%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Can-Fite BioPharma Ltd - 延遲價格・最後更新於 01/07 12:14
    最高位
    0.922
    最低位
    0.890
    開市價
    --
    前收市價
    0.894
    成交量(千)
    0.82
    成交額(百萬)
    0.01
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    24.84
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    2.600 - 0.780
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Can-Fite BioPharma Ltd
    證券代碼
    CANF.US
    所屬板塊
    Biotechnology
    公司業務
    Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
    發行量
    27191543
    公司總部
    10 Bareket Street, Kiryat Matalon, P.O. Box 7537
    公司網址
    http://www.canfite.com
    公司電話
    +972 39241114
    暫無內容

    關於

    Can-Fite BioPharma Ltd(CANF.US)所屬的行業板塊為Biotechnology。
    Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
    詳細公司背景可參考: http://www.canfite.com